NCI-2023-06834

Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

This is a Phase 3 study where researchers are testing if a drug called camizestrant (also known as AZD9833) works better than the standard hormone therapy treatments (either an aromatase inhibitor or tamoxifen) for patients with early-stage breast cancer that is estrogen receptor-positive (ER+) and HER2-negative (HER2-). The patients in this study are at an intermediate-high or high risk of their cancer coming back. They must have already completed treatment to remove or shrink the cancer in the breast and nearby areas (locoregional treatment) and show no signs of cancer remaining.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05952557

Clinical Trial Site: Sinai

To see all available clinical trials click here.